Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
INFI [NASD]
Infinity Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.64 Insider Own0.20% Shs Outstand48.29M Perf Week-2.50%
Market Cap490.14M Forward P/E- EPS next Y-2.80 Insider Trans-64.95% Shs Float46.20M Perf Month-27.14%
Income-126.80M PEG- EPS next Q-0.83 Inst Own98.50% Short Float8.97% Perf Quarter-17.81%
Sales- P/S- EPS this Y-55.30% Inst Trans-15.29% Short Ratio6.11 Perf Half Y-33.05%
Book/sh4.18 P/B2.43 EPS next Y15.40% ROA-46.40% Target Price19.56 Perf Year-74.64%
Cash/sh4.43 P/C2.29 EPS next 5Y3.00% ROE-51.70% 52W Range8.91 - 44.50 Perf YTD-26.50%
Dividend- P/FCF- EPS past 5Y-33.80% ROI- 52W High-77.19% Beta1.14
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low13.92% ATR0.80
Employees180 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)35.39 Volatility9.68% 7.44%
OptionableYes Debt/Eq0.00 EPS Q/Q40.90% Profit Margin- Rel Volume0.89 Prev Close10.60
ShortableYes LT Debt/Eq0.00 EarningsMay 05 Payout- Avg Volume678.18K Price10.15
Recom2.60 SMA20-11.28% SMA50-21.58% SMA200-33.63% Volume602,291 Change-4.25%
06-Mar-13Reiterated Stifel Buy $39 → $50
06-Mar-13Reiterated RBC Capital Mkts Outperform $38 → $55
21-Nov-12Initiated RBC Capital Mkts Outperform $28
24-Aug-12Initiated Stifel Nicolaus Hold
05-Jan-12Initiated Rodman & Renshaw Mkt Perform
16-Apr-09Downgrade Roth Capital Hold → Sell $6 → $4
15-Apr-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
11-Dec-08Downgrade Roth Capital Neutral → Hold
20-Nov-08Reiterated Rodman & Renshaw Mkt Outperform
31-Oct-08Upgrade Susquehanna Financial Neutral → Positive
31-Oct-08Upgrade Roth Capital Hold → Buy $8 → $6
31-Jul-08Downgrade Roth Capital Buy → Hold $11 → $8
06-Jun-08Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $13
15-Jan-08Initiated Roth Capital Buy $11
07-Dec-07Initiated Susquehanna Financial Neutral
03-Aug-07Upgrade Robert W. Baird Neutral → Outperform $15 → $16
12-Jul-07Initiated Jefferies & Co Buy $15
30-Jan-07Initiated Robert W. Baird Neutral $15
11-Mar-14 04:07PM  Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors Business Wire
04:07PM  Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors
10-Mar-14 05:28PM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an EDGAR Online
04:00PM  Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors Business Wire
04:00PM  Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors
03-Mar-14 08:00AM  Infinity to Present at the Upcoming Bernstein Emerging Biotech Conference Business Wire
08:00AM  Infinity to Present at the Upcoming Bernstein Emerging Biotech Conference
28-Feb-14 01:04PM  INFINITY PHARMACEUTICALS, INC. Financials EDGAR Online Financials -5.08%
26-Feb-14 10:20AM  Infinity Pharma Rises on Narrower-than-Expected Loss Zacks
10:20AM  Infinity Pharma Rises on Narrower-than-Expected Loss
06:30AM  Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session Zacks
06:30AM  Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session
25-Feb-14 01:19PM  Why Infinity Pharmaceuticals Inc. Shares Jumped at Motley Fool +15.52%
01:19PM  Why Infinity Pharmaceuticals Inc. Shares Jumped
12:05PM  Infinity Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
12:05PM  Infinity Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
10:14AM  Show of support for Infinity Pharma optionMONSTER
10:14AM  Show of support for Infinity Pharma
08:30AM  Infinity Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
08:12AM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations EDGAR Online
08:00AM  Infinity Provides Company Update and Reports Full-Year 2013 Financial Results Business Wire
07:51AM  INFINITY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online
07:07AM  Q4 2013 Infinity Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
19-Feb-14 08:00AM  Infinity to Participate in 3 Upcoming Conferences Business Wire
11-Feb-14 08:00AM  Infinity Announces the Date of Its Full-Year 2013 Financial Results Conference Call and Webcast Business Wire
10-Feb-14 05:01PM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's Employee Benefi EDGAR Online +5.35%
04-Feb-14 08:16AM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial EDGAR Online
08:00AM  Infinity Announces Promotion of David A. Roth to Chief Medical Officer Business Wire
23-Jan-14 04:03PM  Infinity reports Phase 1 data of IPI-145 clinically active in patients at theflyonthewall.com
04:03PM  Infinity reports Phase 1 data of IPI-145 clinically active in patients
04:00PM  Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum Business Wire
04:00PM  Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum
17-Jan-14 09:10AM  Put sale sees Infinity holding firm optionMONSTER +8.58%
09:10AM  Put sale sees Infinity holding firm
13-Jan-14 09:56AM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl EDGAR Online
09:56AM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl
08:00AM  Infinity Provides Key 2014 Goals and Financial Guidance Business Wire
08:00AM  Infinity Provides Key 2014 Goals and Financial Guidance
06-Jan-14 08:00AM  Infinity to Present at J.P. Morgan Annual Healthcare Conference Business Wire
08:00AM  Infinity to Present at J.P. Morgan Annual Healthcare Conference
31-Dec-13 03:07PM  4 Biggest Biotech Disasters Of 2013 at Forbes
03:07PM  4 Biggest Biotech Disasters Of 2013
27-Dec-13 12:59PM  Keep an Eye on These 3 Revolutionary Cancer Treatments in 2014 at Motley Fool
12:59PM  Keep an Eye on These 3 Revolutionary Cancer Treatments in 2014
12:41PM  The January Effect: It Lives! at Barrons.com
12:41PM  The January Effect: It Lives!
19-Dec-13 06:35AM  The Zacks Analyst Blog Highlights: Celgene, Pharmacyclics, Geron, Incyte and Infinity Pharmaceuticals Zacks
18-Dec-13 12:36PM  Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013 at Motley Fool
12:36PM  Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013
08:00AM  Why Investors Are Writing Off Infinity Pharma at TheStreet
08:00AM  Why Investors Are Writing Off Infinity Pharma
14-Dec-13 08:29AM  The Best- And Worst-Performing Biotech Stocks, Dec. 6 to Dec. 13 at Forbes
08:29AM  The Best- And Worst-Performing Biotech Stocks, Dec. 6 to Dec. 13
12-Dec-13 06:04PM  Nasdaq stocks posting largest percentage decreases AP
01:24PM  Nasdaq stocks posting largest percentage decreases AP
10:23AM  Orphan Drug Designations: Why You Should Care at Seeking Alpha
10:23AM  Orphan Drug Designations: Why You Should Care
11-Dec-13 06:22PM  Nasdaq stocks posting largest percentage decreases AP -10.97%
01:30PM  Nasdaq stocks posting largest percentage decreases AP
08:21AM  Has Infinity Bottomed Out? at Seeking Alpha
08:21AM  Has Infinity Bottomed Out?
10-Dec-13 04:00PM  Positive Data on Infinity Pharma Candidate Zacks
04:00PM  Positive Data on Infinity Pharma Candidate
07:00AM  Bad News Biotechs Of 2013 at Seeking Alpha
09-Dec-13 05:14PM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:36PM  Why Infinity Pharmaceuticals Inc. Shares Temporarily Spiked Higher at Motley Fool
11:24AM  Celgene, Infinity Rise On Blood Cancer Drug Data at Investor's Business Daily
10:03AM  Traders bet Infinity will hold gains optionMONSTER
08-Dec-13 03:02PM  Infinity Pharmaceuticals reports preclinical data at ASH at theflyonthewall.com
10:30AM  Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia and T-Cell Lymphoma at ASH Annual Meeting Business Wire
07-Dec-13 10:01AM  Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin Lymphoma at ASH Annual Meeting Business Wire
10:00AM  Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers Business Wire
06-Dec-13 08:00AM  Infinity to Present at the Oppenheimer 24th Annual Healthcare Conference Business Wire
05-Dec-13 12:01AM  Ditching Big Drugmakers for Biotech Brings Leukemia Boon at Bloomberg
18-Nov-13 05:26AM  Insiders Are Buying Synta Pharmaceuticals at Seeking Alpha
14-Nov-13 01:04PM  INFINITY PHARMACEUTICALS, INC. Financials EDGAR Online Financials
12-Nov-13 01:40PM  Infinity Shares Up, Post Narrower Loss Zacks
11-Nov-13 08:00AM  InPlay: Infinity Pharmaceutical announces its presentation at the Credit Suisse 2013 Healthcare Conference, originally scheduled for Nov 13, 2013, has been rescheduled to Nov 12, 2013, at 8:00 a.m. MT Briefing.com
08:00AM  Infinity Announces New Date and Time for Credit Suisse 2013 Healthcare Conference Presentation and Webcast Business Wire
08-Nov-13 06:02PM  Nasdaq stocks posting largest percentage increases AP +17.38%
04:04PM  Nasdaq stocks posting largest percentage increases AP
02:31PM  Why Infinity Pharmaceuticals Inc. Shares Jumped at Motley Fool
09:19AM  Trader bets Infinity will hold gains optionMONSTER
12:01AM  Infinity Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
07-Nov-13 04:12PM  INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement EDGAR Online
04:00PM  Infinity Reports Third Quarter 2013 Financial Results and Provides Company Update Business Wire
03:51PM  INFINITY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
09:43AM  Infinity Announces Clinical and Preclinical Data to Be Presented at ASH 2013 Annual Meeting Business Wire
09:15AM  InPlay: Infinity Pharmaceutical announces clinical and preclincial data to be presented at ASH 2013 annual meeting; co to provide overview of ASH abstracts on conference call at 4:30 EST today Briefing.com
09:13AM  Infinity Announces Clinical and Preclincial Data to Be Presented at ASH 2013 Annual Meeting Business Wire
07:08AM  Q3 2013 Infinity Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN
06-Nov-13 08:00AM  Infinity to Participate in Three Upcoming Conferences Business Wire -6.48%
25-Oct-13 11:56AM  Infinity Pharmaceuticals Presents A Compelling Risk Reward Ahead Of Imminent Catalysts at Seeking Alpha -5.19%
24-Oct-13 08:00AM  Infinity Announces the Date of its Third Quarter 2013 Financial Results Conference Call and Webcast Business Wire
16-Oct-13 06:16AM  Infinity Pharma bulls bet on bounce optionMONSTER
15-Oct-13 01:54PM  Your first trade for Wednesday at CNBC +5.02%
08-Oct-13 03:14PM  Is This Biotech Company an Underdog Or Just Another Dog? at Motley Fool -5.15%
07-Oct-13 03:14AM  Trader bets on end to Infinity's slide optionMONSTER
27-Sep-13 06:42PM  Top 5 Health-Care Tweets of the Week at Motley Fool
25-Sep-13 07:28PM  4 Healthcare Stock Stories Getting Traction Today at Wall St. Cheat Sheet -5.41%
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SELBY NORMAN CDirectorMar 06Option Exercise8.872,50022,17510,000Mar 10 05:26 PM
Palombella Vito J.Chief Scientific OfficerFeb 25Option Exercise2.044,7369,6614,736Feb 27 04:05 PM
Palombella Vito J.Chief Scientific OfficerFeb 25Sale15.004,73671,0400Feb 27 04:05 PM
Palombella Vito J.Chief Scientific OfficerJan 02Sale13.5275310,1810Jan 06 04:30 PM
EVNIN ANTHONY BDirectorDec 02Sale14.5617,756258,527112,451Dec 04 04:30 PM
EVNIN ANTHONY BDirectorNov 27Sale14.561,20017,472130,207Nov 27 04:40 PM
EVNIN ANTHONY BDirectorNov 26Sale14.72138,9612,045,506131,407Nov 27 04:40 PM
EVNIN ANTHONY BDirectorNov 25Sale15.4023,703365,026270,368Nov 27 04:40 PM
Palombella Vito J.Chief Scientific OfficerSep 27Option Exercise2.044,7369,6614,736Sep 30 06:52 PM
Palombella Vito J.Chief Scientific OfficerSep 27Sale17.284,73681,8370Sep 30 06:52 PM
Perkins Adelene QPres & Chief Executive OfficerSep 13Sale20.5013,076268,096447,535Sep 13 06:00 PM
Perkins Adelene QPres & Chief Executive OfficerSep 12Sale20.8131,924664,390460,611Sep 13 06:00 PM
Palombella Vito J.Chief Scientific OfficerJun 20Option Exercise1.7222,10338,01723,150Jun 21 04:30 PM
Palombella Vito J.Chief Scientific OfficerJun 20Sale18.5323,150429,0670Jun 21 04:30 PM